Skip to content
Jun.08 -- Peter Kinsella, global head of FX strategy at Union Bancaire Privee Ubp SA, discusses the state of play in equities, the rally in risk assets and his outlook for the U.S. dollar. He speaks on “Bloomberg Markets: European Open.”...
Alnylam Pharmaceuticals (ALNY) has announced positive Phase 3 results from the ILLUMINATE-A study of lumasiran for the treatment of primary hyperoxaluria type 1 (PH1).PH1 is an ultra-rare orphan disease caused by excessive oxalate production, and elevated urinary oxalate levels are associated with progression to end-stage kidney disease and other systemic complications.The clinical data was presented at a virtual session of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA).Lumasiran, an investigational RNAi therapeutic, achieved the primary endpoint with a 53.5% mean reduction in urinary oxalate relative to placebo (p=1.7×10-14) and showed a 65.4% mean reduction in urinary oxalate relative to baseline.All tested study secondary endpoints were met, including the proportion of patients achieving near-normalization (84%) or normalization (52%) of urinary oxalate, compared with 0% in the placebo group.Lumasiran also showed an encouraging safety and tolerability profile, with no serious or severe adverse events (AEs) and with mild injection site reactions as...
Jun.08 -- Alex Booth, head of market analysis at Kpler SAS, discusses the outlook for oil supply and demand after after OPEC and its allies agreed to extend historic output curbs by an extra month, promising stricter compliance to ensure members don’t pump more than they pledged. Booth speaks on "Bloomberg Markets: European Open."...
Ericsson expects to take a second-quarter writedown of about 1 billion crowns ($109 million) on product inventory in China, the Swedish telecoms gear maker said on Monday. The company, which has won 5G contracts from three major operators in China, said it expected negative gross margins in China in the quarter reflecting the high initial costs for new products. Ericsson had warned in its first-quarter report that an increasing share of strategic contracts would hurt profitability in the second quarter, primarily due to negative gross margins in China....
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]...
Biopharma AbbVie (ABBV) has announced positive Phase 3 data from a Select-Choice clinical trial, comparing Rinvoq (upadacitinib, 15 mg, once daily) to Bristol-Myers Squibb’s (BMY) Orencia (abatacept) in adults with moderate-to-severe active rheumatoid arthritis (RA).The trial focused on patients with a prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (DMARDs).Rinvoq met the primary endpoint of non-inferiority versus Orencia on change from baseline in Disease Activity Score 28 C-Reactive Protein (DAS28-CRP) at week 12.It also met the key secondary endpoints of superiority versus Orencia on change from baseline in DAS28-CRP at week 12 and proportion of patients achieving clinical remission at week 12 as measured by DAS28-CRP<2.6.This was the sixth and final Phase 3 study from the robust Select rheumatoid arthritis clinical trial program.Rinvoq, Abbvie’s selective and reversible JAK inhibitor, was approved by both the FDA and Europe in 2019 for rheumatoid arthritis.“Despite tremendous progress in the treatment of rheumatoid arthritis,...
Jun.08 -- New Zealand will remove social distancing requirements after reporting zero active cases of Covid-19, indicating it has achieved its aim of eliminating the virus. Prime Minister Jacinda Ardern said Monday at a briefing that all remaining restrictions on people and businesses, other than strict border controls to keep the virus out, will be lifted at midnight tonight, paving the way for a resumption of normal life....
